Home › Merck Receives Complete Response Letter for Investigational Medicine Sugammadex Sodium Injection
 

Keywords :   


Merck Receives Complete Response Letter for Investigational Medicine Sugammadex Sodium Injection

2013-09-23 14:00:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application for sugammadex sodium injection, Mercks investigational medicine for the reversal of neuromuscular blockade induced by rocuronium or vecuronium. Language: English Contact: Media:Pam Eisele, 908-423-5042orSarra Herzog, 908-423-6154orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: complete response letter medicine

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.09Weekly Recap: AkzoNobel, BASF, Axalta, PPG Top This Weeks Stories
28.09Post-Tropical Cyclone Helene Public Advisory Number 20
28.09Hurricane Isaac Graphics
28.09Hurricane Isaac Forecast Discussion Number 10
28.09Hurricane Isaac Wind Speed Probabilities Number 10
28.09Hurricane Isaac Public Advisory Number 10
28.09Summary for Hurricane Isaac (AT5/AL102024)
28.09Hurricane Isaac Forecast Advisory Number 10
More »